CD9 and myeloid sarcoma: Specifically, CD81, CD63, and CD9 were decreased in comparison to ACs (p = 0.0007, p = 0.0068, and p = 0.0004, respectively) and ONDs (p = 0.0005, p < 0.0001, and p = 0.006, respectively), but not to HVs and MS patients.